A Phase III randomised, Open-Label, Multi-centre study Assessing the Clinical Benefit of Isatuximab (SAR650984) in Combination with Bortezomib (Velcade), Lenalidomide (Revlimid) and Dexamethasone Versus Bortezomib, Lenalidomide and Dexamethasone in Patients with Newly Diagnosed Multiple Myeloma not Eligible for Transplant (IMROZ)

Project: Research

Project Details

Project Description

NMA HREC Reference Number: HREC/17/SVH/289
NMA SSA Reference Number: SSA/18/MonH/49
Monash Health Ref: RES-18-0000-058X
Effective start/end date24/05/1923/05/24


  • clinical trial
  • treatment efficacy
  • myeloma